|
시장보고서
상품코드
2080407
면역억제제 시장 : 약제 클래스별, 투여 경로, 브랜드 상황, 적응증, 환자 유형, 유통 채널별 - 세계 예측(2026-2032년)Immunosuppressant Drugs Market by Drug Class, Route Of Administration, Brand Status, Indication, Patient Type, Distribution Channel - Global Forecast 2026-2032 |
||||||
360iResearch
면역억제제 시장은 2032년까지 연평균 복합 성장률(CAGR) 9.07%로 성장해 120억 달러 규모로 확대될 것으로 예측됩니다.
| 주요 시장 통계 | |
|---|---|
| 기준 연도(2025년) | 65억 3,000만 달러 |
| 추정 연도(2026년) | 71억 달러 |
| 예측 연도(2032년) | 120억 달러 |
| CAGR(%) | 9.07% |
면역억제제는 장기 이식 후 거부 반응을 예방하고, 류마티스 관절염, 건선, 염증성 장질환, 루푸스, 다발성 경화증, 중증 아토피성 질환 등 면역 매개성 질환을 관리하는 데 필수적인 치료법입니다. 이 시장에는 타크롤리무스나 사이클로스포린 등의 칼시뉴린 억제제, 미코페놀산 모페틸이나 아자티오프린 등의 항증식제, 코르티코스테로이드, mTOR 억제제, 야누스키나제 억제제, 바이오의약품, 바이오시밀러, 그리고 새롭게 등장한 표적형 면역조절제 등이 포함됩니다.
제약사, 보험사, 의료 제공업체, 투자자에게 있어 면역억제제 시장은 ‘지속적인 효능을 유지하면서 감염증, 악성 종양, 신독성, 대사성 합병증 및 약물 상호작용의 위험을 줄인다’는 두 가지 사명에 의해 형성되고 있습니다. 경쟁 우위는 차별화된 안전성 프로파일, 치료제 모니터링, 바이오시밀러 접근성, 환자의 복약 순응도 지원, 그리고 이식 및 만성 염증성 질환 적응증에 걸친 근거 창출로 점차 전환되고 있습니다.
면역억제제 분야의 획기적인 변화
이 분야는 광범위한 면역 억제에서 선택적이고 작용기전에 기반한 면역 조절로 전환되고 있습니다. 기존 약물은 이식 의학 분야에서 여전히 기초적인 역할을 수행하고 있지만, 바이오의약품과 표적 지향형 저분자 약물은 사이토카인, 림프구 이동, 세포 내 신호 전달 및 공동 자극 경로에 초점을 맞추어 자가면역 질환의 치료 경로를 확대되고 있습니다. 이러한 변화로 인해 질환 관리가 개선되는 한편, 환자에 대한 정밀한 선별과 장기적인 안전성 모니터링에 대한 기대도 높아지고 있습니다.
인공지능(AI)의 누적 영향
인공지능은 표적 식별 및 분자 스크리닝부터 시판 후 안전성 모니터링에 이르기까지, 면역억제제의 전체 밸류체인에 영향을 미치기 시작했습니다. 머신러닝 모델은 오믹스 데이터셋, 면역 세포 시그니처, 전자 진료 기록, 영상 진단 데이터, 임상시험 데이터를 분석하여, 기존 방법만으로는 감지하기 어려웠던 치료 반응자 하위 집단이나 잠재적인 안전성 신호를 파악할 수 있습니다.
주요 지역에 대한 인사이트
북미는 선진적인 이식 인프라, 전문 약국 네트워크, 생물학적 제제의 높은 보급률, 그리고 활발한 임상 연구 활동 덕분에 여전히 고부가가치의 면역억제제 시장으로 자리 잡고 있습니다. 미국은 대규모 이식 건수, 자가면역 질환 치료의 보급, 그리고 첨단 치료법의 신속한 도입을 통해 수요를 뒷받침하고 있는 반면, 캐나다는 공공 지원을 통한 접근성, 의료 기술 평가, 의약품 안전성 감시, 그리고 바이오시밀러로의 전환 정책을 중시하고 있습니다.
주요 그룹에 대한 인사이트
G7 국가들은 높은 의료비 지출, 선진화된 이식 네트워크, 생물학적 제제의 활용, 확립된 의약품 안전성 감시 시스템, 그리고 임상 지침의 적극적인 도입에 힘입어, 면역억제제에 있어 상업적으로 가장 성숙한 수요 기반을 형성하고 있습니다. 이 그룹 내에서 미국, 일본, 독일, 프랑스, 영국, 이탈리아, 캐나다는 임상 개발, 가격 책정 관련 논의, 바이오시밀러 도입, 그리고 승인 후 증거 창출에 있어 중심적인 역할을 수행하고 있습니다.
주요 국가에 대한 인사이트
미국은 활발한 이식 활동, 생물학적 제제의 보급, 전문 약국을 통한 유통, 그리고 활발한 임상시험 활동에 힘입어 가장 영향력 있는 시장으로 자리매김하고 있습니다. 캐나다는 비용 대비 효과, 바이오시밀러 정책, 그리고 각 주의 의료 제도 내 공평한 접근성을 중시하는 반면, 멕시코에서는 민간 병원, 공공 조달, 그리고 만성 질환 관리의 확대를 통해 수요가 증가하는 추세를 보이고 있습니다.
업계 리더를 위한 실천적인 제안
업계 리더는 단순한 점진적인 효능 주장에만 의존하기보다는 차별화된 안전성, 지속적인 효능, 그리고 실제 임상 현장에서의 성과를 우선시해야 합니다. 이식 의학 분야에서는 신독성, 감염 위험, 거부 반응 위험 및 복약 순응도 부담을 경감시키는 전략이 임상적·상업적 측면에서 의미 있는 차별화를 가져올 가능성이 있습니다. 자가면역 질환의 경우, 치료제 선택지가 점점 늘어나면서 환자 세분화와 바이오마커에 기반한 시장 포지셔닝이 필수적입니다.
조사 방법
본 요약본은 이식 등록부, 규제 당국, 동료 심사를 거친 의학 문헌, 의료 기술 평가 기관, 임상 지침, 의약품 정책 관련 간행물 등 검증된 공개 정보원 및 기관 정보원을 바탕으로 한 2차 조사에 기초하고 있습니다. 주요 참고 자료로는 Global Observatory on Donation and Transplantation(세계 장기 기증·이식 관측소), 각국의 이식 시스템, 미국 식품의약국(FDA), 유럽의약품청(EMA), 그리고 이식, 류마티스학, 소화기내과, 피부과학, 신장학 등 각 분야의 공인된 임상 학회에서 제공한 데이터가 포함됩니다.
결론
면역억제제 시장은 점점 더 전문화되어 가고 있으며, 근거 중심의 단계로 전환되고 있습니다. 이식 의학 분야에서는 이미 효과가 입증된 유지 요법이 여전히 주류를 이루고 있는 반면, 자가면역 질환 및 염증성 질환의 관리에 있어서는 표적형 생물학적 제제, 바이오시밀러, 저분자 약제가 점점 더 중요한 역할을 담당하고 있습니다. 수요는 지속적인 임상적 필요성, 진단 범위의 확대, 치료의 표준화 진전, 그리고 유해한 면역 반응을 억제할 수 있는 치료법에 대한 지속적인 의존에 의해 뒷받침되고 있습니다.
자주 묻는 질문
목차
제1장 서문
제2장 조사 방법
제3장 주요 요약
제4장 시장 개요
제5장 시장 인사이트
제6장 AI의 누적 영향(2026년)
제7장 면역억제제 시장 : 약제 클래스별
제8장 면역억제제 시장 : 투여 경로별
제9장 면역억제제 시장 : 브랜드 상황별
제10장 면역억제제 시장 : 적응증별
제11장 면역억제제 시장 : 환자 유형별
제12장 면역억제제 시장 : 유통 채널별
제13장 면역억제제 시장 : 지역별
제14장 면역억제제 시장 : 그룹별
제15장 면역억제제 시장 : 국가별
제16장 경쟁 구도
제17장 기업 개요
KTH 26.07.13The Immunosuppressant Drugs Market is projected to grow by USD 12.00 billion at a CAGR of 9.07% by 2032.
| KEY MARKET STATISTICS | |
|---|---|
| Base Year [2025] | USD 6.53 billion |
| Estimated Year [2026] | USD 7.10 billion |
| Forecast Year [2032] | USD 12.00 billion |
| CAGR (%) | 9.07% |
Immunosuppressant drugs are essential therapies for preventing organ transplant rejection and controlling immune-mediated diseases, including rheumatoid arthritis, psoriasis, inflammatory bowel disease, lupus, multiple sclerosis, and severe atopic conditions. The market spans calcineurin inhibitors such as tacrolimus and cyclosporine, antiproliferative agents such as mycophenolate mofetil and azathioprine, corticosteroids, mTOR inhibitors, Janus kinase inhibitors, biologics, biosimilars, and emerging targeted immunomodulators.
For manufacturers, payers, providers, and investors, the immunosuppressant drugs market is shaped by a dual mandate: maintain durable efficacy while reducing infection, malignancy, nephrotoxicity, metabolic complications, and drug-drug interaction risks. Competitive advantage is moving toward differentiated safety profiles, therapeutic drug monitoring, biosimilar access, patient adherence support, and evidence generation across transplant and chronic inflammatory indications.
Transformative Shifts in the Immunosuppressant Landscape
The landscape is shifting from broad immune suppression toward selective, mechanism-based immunomodulation. Conventional agents remain foundational in transplant care, but biologics and targeted small molecules are expanding treatment pathways in autoimmune disorders by focusing on cytokines, lymphocyte trafficking, intracellular signaling, and co-stimulation pathways. This shift is improving disease control while raising expectations for precision patient selection and long-term safety surveillance.
Biosimilars are also reshaping access and pricing dynamics, especially in markets with mature regulatory pathways. As patents expire for leading biologic immunosuppressive and immunomodulatory therapies, competition is increasing pressure on net prices while expanding access for patients and health systems. At the same time, specialty pharmacy models, risk evaluation programs, and payer prior authorization requirements are influencing treatment sequencing and prescribing behavior.
Transplant protocols are becoming more individualized as clinicians balance rejection prevention with infection risk and renal preservation. The adoption of pharmacogenomics, therapeutic drug monitoring, donor-derived cell-free DNA testing, infection screening, and digital adherence tools is reinforcing a shift from standardized maintenance regimens to evidence-guided, patient-specific immunosuppression strategies.
Cumulative Impact of Artificial Intelligence
Artificial intelligence is beginning to affect the full immunosuppressant drug value chain, from target identification and molecule screening to post-market safety monitoring. Machine learning models can analyze omics datasets, immune-cell signatures, electronic health records, imaging outputs, and clinical trial data to identify responder subgroups and potential safety signals that would be difficult to detect through traditional methods alone.
In clinical practice, AI-enabled decision support is most relevant to precision dosing and risk prediction. Tacrolimus and cyclosporine require careful monitoring because of narrow therapeutic windows, variable metabolism, and clinically significant interactions. AI models trained on therapeutic drug monitoring data, pharmacogenomic markers such as CYP3A5 status, liver and kidney function, age, weight, and concomitant medications can support more individualized dose adjustments, although clinician oversight, prospective validation, and regulatory alignment remain essential.
The cumulative impact is stronger evidence generation, faster pharmacovigilance, and more efficient trials. AI can improve patient recruitment for rare transplant cohorts and autoimmune subtypes, simulate protocol scenarios, and support real-world evidence analysis. However, adoption depends on transparent algorithms, high-quality data, cybersecurity, interoperability, and reducing bias across diverse populations.
Key Regional Insights
North America remains a high-value immunosuppressant drugs market due to advanced transplant infrastructure, specialty pharmacy networks, high biologic adoption, and strong clinical research activity. The United States anchors demand through large transplant volumes, autoimmune disease treatment uptake, and rapid use of advanced therapeutics, while Canada emphasizes publicly supported access, health technology assessment, pharmacovigilance, and biosimilar switching policies.
Europe combines mature transplant systems with strong regulatory oversight and expanding biosimilar penetration. The European Medicines Agency's established biosimilar framework has supported competition across immunology and inflammation therapies, while national reimbursement bodies continue to influence uptake. Western Europe shows strong adoption of biologics and targeted small molecules, whereas Central and Eastern Europe are more sensitive to pricing, tendering, and formulary access.
Asia-Pacific is the fastest-evolving opportunity area as China, India, Japan, South Korea, and Australia expand specialty care capacity, local manufacturing, and transplant services. Japan and Australia offer mature reimbursement and high clinical standards, while China and India present large patient pools and growing demand for affordable generics, biosimilars, and transplant medicines. Latin America is led by Brazil and Mexico, where public procurement and private specialty care coexist, but access variability remains significant. The Middle East, particularly GCC countries, is investing in tertiary care and transplant programs, while Africa remains constrained by limited transplant infrastructure, affordability barriers, workforce shortages, and uneven access to specialist-led immunology care.
Key Group Insights
The G7 represents the most commercially mature demand base for immunosuppressant drugs, driven by high healthcare spending, advanced transplant networks, biologic utilization, established pharmacovigilance systems, and strong clinical guideline adoption. Within this group, the United States, Japan, Germany, France, the United Kingdom, Italy, and Canada are central to clinical development, pricing debates, biosimilar adoption, and post-approval evidence generation.
The European Union is a major regulatory and access benchmark due to harmonized medicine authorization through the European Medicines Agency and country-level reimbursement evaluation. EU policy support for biosimilars, medicine safety monitoring, pharmacovigilance, and cross-border regulatory standards makes the region highly influential for manufacturers seeking scalable immunosuppressant drug strategies.
BRICS countries are increasingly important for patient access, manufacturing resilience, and generic and biosimilar supply. China and India are expanding domestic pharmaceutical capabilities and specialty care access, Brazil supports regional demand through public and private channels, Russia retains substantial clinical need despite access constraints, and South Africa provides an important gateway for sub-Saharan access despite affordability challenges. ASEAN markets show rising demand as specialist capacity improves in Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines, with wide variation in reimbursement maturity. GCC countries are prioritizing tertiary hospitals, transplant services, and high-cost specialty medicines, supported by healthcare diversification strategies. NATO countries overlap heavily with North American and European demand centers, reinforcing procurement security, supply-chain resilience, and regulatory alignment across advanced healthcare systems.
Key Country Insights
The United States is the most influential country market, supported by high transplant activity, strong biologic uptake, specialty pharmacy distribution, and intensive clinical trial activity. Canada emphasizes cost-effectiveness, biosimilar policy, and equitable access across provincial systems, while Mexico shows demand growth through private hospitals, public procurement, and expanding chronic disease management.
Brazil is Latin America's leading immunosuppressant opportunity due to its large population, public health system purchasing, and established transplant activity. In Europe, the United Kingdom, Germany, France, Italy, and Spain combine advanced immunology care with payer scrutiny, biosimilar uptake, and national treatment guidelines. Germany and France remain key access and evidence-generation markets, while the United Kingdom's health technology assessments strongly influence value-based positioning. Russia retains demand for transplant and autoimmune therapies but faces supply, pricing, and geopolitical constraints.
China and India are critical growth markets because of large autoimmune patient populations, improving diagnosis, expanding hospital capacity, and strong generic and biosimilar manufacturing. Japan offers a mature, innovation-oriented market with high safety expectations and aging-population demand. South Korea combines advanced biologics manufacturing, high digital health adoption, and sophisticated specialty care, while Australia benefits from structured reimbursement, clinical guideline adoption, and strong transplant and immunology services.
Actionable Recommendations for Industry Leaders
Industry leaders should prioritize differentiated safety, durable efficacy, and real-world outcomes rather than relying solely on incremental efficacy claims. In transplant medicine, strategies that reduce nephrotoxicity, infection risk, rejection risk, and adherence burden can create meaningful clinical and commercial separation. In autoimmune diseases, patient segmentation and biomarker-led positioning will be essential as treatment classes become more crowded.
Manufacturers should strengthen biosimilar and lifecycle strategies, including device improvements, patient support programs, therapeutic drug monitoring integration, formulation optimization, and evidence packages for payers. Companies competing in price-sensitive markets should align portfolios around reliable supply, quality certification, cold-chain readiness, and locally relevant access models.
Vendors should also invest in AI-enabled pharmacovigilance, precision dosing partnerships, and real-world evidence platforms. Collaborations with transplant centers, specialty pharmacies, laboratories, and digital health partners can improve adherence, monitor safety, and demonstrate value to payers. Regulatory teams should prepare for increasing scrutiny of AI tools, data integrity, cybersecurity, and post-market risk management.
Research Methodology
This executive summary is based on secondary research from verified public and institutional sources, including transplant registries, regulatory agencies, peer-reviewed medical literature, health technology assessment bodies, clinical guidelines, and pharmaceutical policy publications. Key reference categories include data from the Global Observatory on Donation and Transplantation, national transplant systems, the U.S. FDA, the European Medicines Agency, and recognized clinical societies in transplantation, rheumatology, gastroenterology, dermatology, and nephrology.
The analysis triangulates demand indicators such as transplant volumes, autoimmune disease burden, biologic and biosimilar adoption, reimbursement structures, regulatory pathways, and regional healthcare capacity. Market interpretation emphasizes evidence-backed trends rather than unverified projections, with qualitative assessment of competitive dynamics, access conditions, technology adoption, and therapeutic innovation.
Regional, group, and country insights were developed by comparing healthcare infrastructure, specialty medicine access, pricing and reimbursement maturity, regulatory frameworks, transplant capacity, pharmacovigilance systems, and pharmaceutical manufacturing capabilities. The methodology prioritizes data consistency, source credibility, and practical relevance for manufacturers, investors, payers, distributors, and healthcare providers.
Conclusion
The immunosuppressant drugs market is entering a more specialized, evidence-driven phase. Transplant medicine continues to rely on proven maintenance therapies, while autoimmune and inflammatory disease management is increasingly shaped by targeted biologics, biosimilars, and small molecules. Demand is supported by durable clinical need, expanding diagnosis, rising treatment standardization, and sustained reliance on therapies that can control harmful immune activity.
Future performance will depend on balancing access, affordability, efficacy, and safety. Organizations that combine strong clinical evidence with real-world outcomes, precision dosing, pharmacovigilance, and patient support will be best positioned. As AI, biosimilars, and biomarker-led care mature, the competitive landscape will reward organizations that can deliver measurable patient value across diverse healthcare systems.
Table of Contents
1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Definition
- 1.3. Market Segmentation & Coverage
- 1.4. Years Considered for the Study
- 1.5. Currency Considered for the Study
- 1.6. Language Considered for the Study
- 1.7. Key Stakeholders
2. Research Methodology
- 2.1. Introduction
- 2.2. Research Design
- 2.2.1. Primary Research
- 2.2.2. Secondary Research
- 2.3. Research Framework
- 2.3.1. Qualitative Analysis
- 2.3.2. Quantitative Analysis
- 2.4. Market Size Estimation
- 2.4.1. Top-Down Approach
- 2.4.2. Bottom-Up Approach
- 2.5. Data Triangulation
- 2.6. Research Outcomes
- 2.7. Research Assumptions
- 2.8. Research Limitations
3. Executive Summary
- 3.1. Introduction
- 3.2. CXO Perspective
- 3.3. Market Size & Growth Trends
- 3.4. Market Share Analysis, 2025
- 3.5. FPNV Positioning Matrix, 2025
- 3.6. New Revenue Opportunities
- 3.7. Next-Generation Business Models
- 3.8. Industry Roadmap
4. Market Overview
- 4.1. Introduction
- 4.2. Industry Ecosystem & Value Chain Analysis
- 4.2.1. Supply-Side Analysis
- 4.2.2. Demand-Side Analysis
- 4.2.3. Stakeholder Analysis
- 4.3. Market Dynamics
- 4.3.1. Key Drivers
- 4.3.2. Key Restraints
- 4.3.3. Key Opportunities
- 4.3.4. Key Challenges
- 4.4. Porter's Five Forces Analysis
- 4.5. PESTLE Analysis
- 4.6. Market Outlook
- 4.6.1. Near-Term Market Outlook (0-2 Years)
- 4.6.2. Medium-Term Market Outlook (3-5 Years)
- 4.6.3. Long-Term Market Outlook (5-10 Years)
- 4.7. Go-to-Market Strategy
5. Market Insights
- 5.1. Consumer Insights & End-User Perspective
- 5.2. Consumer Experience Benchmarking
- 5.3. Opportunity Mapping
- 5.4. Distribution Channel Analysis
- 5.5. Pricing Trend Analysis
- 5.6. Regulatory Compliance & Standards Framework
- 5.7. ESG & Sustainability Analysis
- 5.8. Disruption & Risk Scenarios
- 5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Immunosuppressant Drugs Market, by Drug Class
- 7.1. Biologics
- 7.1.1. Fusion Proteins
- 7.1.2. Monoclonal Antibodies
- 7.1.2.1. Interleukin Inhibitors
- 7.1.2.2. T Cell Activation Inhibitors
- 7.1.2.3. Tnf Inhibitors
- 7.2. Small Molecules
- 7.2.1. Antimetabolites
- 7.2.2. Calcineurin Inhibitors
- 7.2.3. Corticosteroids
- 7.2.4. Mtor Inhibitors
8. Immunosuppressant Drugs Market, by Route Of Administration
- 8.1. Intravenous
- 8.2. Oral
- 8.3. Subcutaneous
9. Immunosuppressant Drugs Market, by Brand Status
- 9.1. Branded
- 9.2. Generic
10. Immunosuppressant Drugs Market, by Indication
- 10.1. Autoimmune Disease
- 10.1.1. Inflammatory Bowel Disease
- 10.1.2. Lupus
- 10.1.3. Psoriasis
- 10.1.4. Rheumatoid Arthritis
- 10.2. Organ Transplantation
- 10.2.1. Heart Transplant
- 10.2.2. Kidney Transplant
- 10.2.3. Liver Transplant
- 10.2.4. Lung Transplant
11. Immunosuppressant Drugs Market, by Patient Type
- 11.1. Adult
- 11.2. Pediatric
12. Immunosuppressant Drugs Market, by Distribution Channel
- 12.1. Hospital Pharmacy
- 12.2. Online Pharmacy
- 12.3. Retail Pharmacy
13. Immunosuppressant Drugs Market, by Region
- 13.1. Asia-Pacific
- 13.2. North America
- 13.3. Latin America
- 13.4. Europe
- 13.5. Middle East
- 13.6. Africa
14. Immunosuppressant Drugs Market, by Group
- 14.1. ASEAN
- 14.2. GCC
- 14.3. European Union
- 14.4. BRICS
- 14.5. G7
- 14.6. NATO
15. Immunosuppressant Drugs Market, by Country
- 15.1. United States
- 15.2. Canada
- 15.3. Mexico
- 15.4. Brazil
- 15.5. United Kingdom
- 15.6. Germany
- 15.7. France
- 15.8. Russia
- 15.9. Italy
- 15.10. Spain
- 15.11. China
- 15.12. India
- 15.13. Japan
- 15.14. Australia
- 15.15. South Korea
16. Competitive Landscape
- 16.1. Market Concentration Analysis, 2025
- 16.1.1. Concentration Ratio (CR)
- 16.1.2. Herfindahl Hirschman Index (HHI)
- 16.2. Recent Developments & Impact Analysis, 2025
- 16.3. Product Portfolio Analysis, 2025
- 16.4. Benchmarking Analysis, 2025
17. Company Profiles
- 17.1. AbbVie Inc
- 17.2. Alkem Laboratories Limited
- 17.3. Amgen Inc.
- 17.4. Astellas Pharma Inc
- 17.5. Aurobindo Pharma Limited
- 17.6. Bristol Myers Squibb Company
- 17.7. Cadila Healthcare Ltd.
- 17.8. Cipla Ltd.
- 17.9. Concord Biotech Limited
- 17.10. CSL Behring LLC
- 17.11. Dr. Reddy's Laboratories Ltd
- 17.12. Eli Lilly and Company
- 17.13. F. Hoffmann La Roche AG
- 17.14. Fresenius SE & Co. KGaA
- 17.15. GlaxoSmithKline plc
- 17.16. Glenmark Pharmaceuticals Ltd.
- 17.17. Hikma Pharmaceuticals plc
- 17.18. Intas Pharmaceuticals Ltd.
- 17.19. Johnson & Johnson
- 17.20. Lupin Ltd
- 17.21. Mitsubishi Tanabe Pharma Corporation
- 17.22. Novartis AG
- 17.23. Panacea Biotec
- 17.24. Pfizer Inc
- 17.25. Sandoz Group AG
- 17.26. Sanofi S.A.
- 17.27. Sebela Pharmaceuticals Inc.
- 17.28. Strides Pharma Global Pte Ltd.
- 17.29. Sun Pharmaceutical Industries Ltd
- 17.30. Teva Pharmaceutical Industries Ltd
- 17.31. Veloxis Pharmaceuticals Inc
- 17.32. Viatris Inc
- 17.33. Zydus Lifesciences Limited
